Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, April 1, 2021
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
[ Thu, Apr 01st 2021
] - WOPRAI
Sumant Kulkarni Maintained (BTAI) at Strong Buy with Decreased Target to $95 on, Apr 1st, 2021
Sumant Kulkarni of Canaccord Genuity, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $110 to $95 on, Apr 1st, 2021.
Sumant has made no other calls on BTAI in the last 4 months.
There is 1 other peer that has a rating on BTAI. Out of the 1 peers that are also analyzing BTAI, 0 agree with Sumant's Rating of Hold.
This is the rating of the analyst that currently disagrees with Sumant
- Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $99 on, Monday, February 1st, 2021
